PiXL Corneal Remodeling Non Invasive Solutions for Vision Improvement

Rajesh K. Rajpal, MDChief Medical Officer, Avedro, Inc.

Medical Director & Founder, See Clearly Vision GroupClinical Associate Professor, Georgetown University

Financial Disclosures

Forward Looking Statements for Avedro: This presentation contains “forward-looking statements” within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and“future” or similar expressions are intended to identify forward-looking statements. Any forward-looking statements are based onmanagement’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actualresults to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion ofrisks and uncertainties and other important factors, any of which could cause Avedro’s actual results to differ from those contained inthe forward-looking statements, see the section titled “Risk Factors” in Avedro’s prospectus dated February 13, 2019 filed pursuantto Rule 424(b)(4) as well as discussions of potential risks, uncertainties and other important factors in Avedro’s subsequent filingswith the Securities and Exchange Commission. All information in this presentation is as of the date of the release, and Avedroundertakes no duty to update this information unless required by law.

‒ Alcon‒ Allergan‒ Avedro‒ Bausch

‒ J&J‒ Kala‒ Mimetogen‒ Oyster Point

‒ RPS‒ RxSight‒ Shire/Takeda‒ Tear Solutions

Avedro’s Approach: Non-invasively Stabilizing and Reshaping the CorneaCorneal Remodeling Technology

Uniform Activation to Stabilize

Targeted Activation to Reshape

Pharmaceutical Application

TMTM

The Mosaic System, Boost Goggles, and transepithelial drug formulations are not sold in the United States

Postoperative Corneal AdjustabilityUnmet Need & Proposed Solution

Opportunities

Solution

• Cataracts - Patients who have had a surgery to treat

cataracts may require some form of refractive

correction following the procedure

• Presbyopia - in post-refractive surgery patients

• Corneal remodeling for non-invasive reshapingthe cornea without ablation or incision

Filling the Refractive Option Void Non-invasive solution for presbyopia

GLASSES DROPS(not approved)

MULTI-FOCAL CONTACTS

INLAYSLASIK REFRACTIVE LENS EXCHANGEDROPS & UV LIGHT

(dependence) (independence)

Most Invasive

Least Invasive

30 minutes to vision renewal

Investigational. Not FDA approved.

One time, non-invasive corneal remodeling treatment

Spectacle independenceBinocular UNVA of J2 or better

No halo or loss of CDVA

Non-invasive, simple procedure1-2 day recovery

Long-term stability of CXL

PiXL for Vision ImprovementNon-invasive corneal remodeling

Investigational. Not FDA approved.

Central Activationfor Myopia

Peripheral Activation for Presbyopia

5

4

Image courtesy of Pavel Stodulka, MD

Clinical case example from Jeff Machat, MD

53 year old male +1.25 D correction

Pre-PiXL

Post-PiXL

More than 200 eyes treated internationally with PiXL to date

Investigational. Not FDA approved.

PiXL for PresbyopiaSpatially targeted, epithelium-on, accelerated cross-linking

• Midperipheral cross-linking, no UVA applied to central cornea

• Image above: High resolution OCT image showing mid peripheral corneal stromal demarcation line after epi-ON PiXL with oxygen

• A potential non-invasive solution for presbyopia

• Filling a gap in refractive treatment options

• Drops, UV light and O2

• Targeted corneal reshaping with long-term durability of cross-linking

• Likely advantageous for post operative cornea adjustability

• Early clinical results are promising

• Multicenter Phase II Study in 2019

Mosaic SystemProprietary computer software and UVA beam forming technology

Boost Goggles

New Drug FormulationsProprietary single-use drug formulations

Investigational. Not FDA approved.